Krishna Institute Of Medical Sciences Limited · NSE:KIMS
Krishna Institute Of Medical Sciences — Q1 FY2025 Earnings Presentation
34 slides from Krishna Institute Of Medical Sciences's earnings presentation, Aug 7, 2024
Slide 1: Investor Presentation filing letter to BSE and NSE
07th August 2024 The General Manager, The Manager, Department of Corporate Services Listing Department Bombay Stock Exchange Ltd (BSE) National Stock Exchange of India Limited, Phiroze Jheejheebhoy Towers, Exchange Plaza, 5th Floor, Dalal Street, Plot No.C/1, 'G' Block, Mumbai - 400 001. Bandra - Ku
Slide 2: Q1 FY25 Update
Q1 FY25 UPDATE Private & Confidential
Slide 3: Driven by a Vision
Driven by a Vision Affordable Quality Care VISION: Best-in-Class Facilities Patient Centric Systems & Processes S To be the most preferred NT healthcare services brand by TIE providing affordable care and best PA clinical outcomes to patients. Clinical Outcome Driven Excellence And to be the best pl
Slide 4: Multi Specialty Care
Multi Specialty Care Brain Eyes Bones and Spine Radiology • Neurology • Ophthalmology • Orthopedics • Imaging • Neurosurgery Gastro Intestinal Tract • Arthroscopic Surgery • Interventional Radiology • Psychiatry • Medical Gastroenterology • Spine Surgery Lab Services • Neuro Rehabilitation • Surgica
Slide 5: KIMS at a Glance
KIMS at a Glance Telangana Secunderabad (1000) Maharashtra Paradise Circle (290) (Shifted to Begumpet) Nagpur (334) Kondapur (200) Nashik (325) Gachibowli (237) Thane (Under Construction: 300) Andhra Pradesh Visakhapatnam (Unit 1 - 469 & Unit 2 - 250) Srikakulam (200) Rajahmundry (195) Karnataka Ong
Slide 6: Dr. B. Bhaskar Rao - Visionary Behind KIMS
Dr. B. Bhaskar Rao - Visionary Behind KIMS Chairman & Managing Director A legend in CT Surgery, Dr. Bollineni Bhaskar Rao {MBBS, MS, DNB (CT Surgery)} is one of the very few Cardio- Thoracic Surgeons in the country, who performed over 30000 surgeries in his career spanning over more than 25 years. W
Slide 7: Dr. Abhinay Bollineni
Dr. Abhinay Bollineni Chief Executive Officer Dr. Abhinay Bollineni joined KIMS Hospitals in 2013 and spent the next couple of years in Hospital Operations before taking charge of Strategy & Marketing for the Group in 2015. In a short span of 5 years, KIMS expanded and opened five additional units (
Slide 8: Board of Directors
Board of Directors Dr. Bhaskara Rao Bollineni Dr. Abhinay Bollineni Mrs. Anitha Dandamudi Mr. Saumen Chakraborty Chairman & Managing Director Chief Executive Officer Whole-time Director Independent Director, Chairman (Audit Committee) Mr. Adwik Bollineni Mr. Venkata Ramudu Jasthi Mrs. Y. Prameela Ra
Slide 9: Organizational Announcement
Organizational Announcement Please welcome Mr. Sreenath Reddy. He joins as the Director - Business Strategy and Mergers & Acquisitions. We are happy to announce that Sreenath, a seasoned leader from the Indian Healthcare Sector joins us in our ambitious growth journey. Sreenath comes with a wealth o
Slide 10: Shareholding Pattern - As on 30 June, 2024
Shareholding Pattern - As on 30 June, 2024 th Retail & Others, Retail Pre IPO, 3.8% 7.2% Promoter & Promoter Share Holder No of Shares Share Holding % Category Group, 38.8% Promoter 3,10,51,304 38.8% ICICI Ventures 7,75,758 1.0% Sbi Mf 57,64,561 7.2% DII FII, 17.7% Axis Mf 35,39,962 4.4% DII Hdfc Mf
Slide 11: Modern Medical Technology
Modern Medical Technology 4-Arm HD da Vinci O-Arm Scanner Spy Glass Fibroscan Robotic Surgical Multi-dimensional surgical State of the art add on to Specialized non-invasive System imaging platform optimized ERCP that allows doctors to diagnostic ultrasound-based Facilitates complex for use in spine
Slide 12: Many Firsts...
Many Firsts... • First in Asia in to do Trans catheter • India’s first COVID Double Lung • Number 1 in Nephrology treatments in Tricuspid Valve replacement transplant done in 2020 Andhra Pradesh* procedure done in 2018 • India’s first Breathing Lung transplant • Number 1 in Neurosurgery & Poly • Lar
Slide 13: Key Accomplishments
Key Accomplishments NAL ACCRED ATIO IT N AT ER ION INT QU Y ET LI AF A TY & PAT I E N T S Pharmacie De Qualite (PDQ) American Accreditation Commission Certification Overall PDQ Evaluation ‘Best Patient Friendly Hospital’ Ranked No. 1 Hospital International (AACI) Performance Score - 98% AHPI Health
Slide 14: Consistent Performer over 2 decades
Consistent Performer over 2 decades (Rupees in Millions) 25,112 6,232 22,235 5,766 % .1% : 2 7.1 16,711 : 3 0 5,217 R CAG GR CA 11,287 2,412 4,280 773 1,311 317 263 42 2005 2010 2015 2020 2022 2023** 2024 2005 2010 2015 2020 2022*** 2023** 2024 No. of No. of No. of No. of No. of No. of No. of Hospit
Slide 15: Q1 FY25 Updates
Q1 FY25 Updates 14 Private & Confidential
Slide 16: Financial & Operational Highlights - 1/2
Financial & Operational Highlights - 1/2 (Rupees in Cr) FINANCIAL HIGHLIGHTS Q1 FY 25 Consolidated • Gross revenue of INR 693 Cr, a growth of 13.8% on YoY and 8.7% on QoQ basis. • EBITDA of INR 184 Cr, a growth of 14.9% on YoY and 13.0% on QoQ basis. • EBITDA margin at 26.6% vs. 26.3% in Q1 FY24 and
Slide 17: Financial & Operational Highlights - 2/2
Financial & Operational Highlights - 2/2 OPERATIONAL Q1 FY 25 Consolidated HIGHLIGHTS • ARPOB grew by 21.3% and 12.2% on YoY and QoQ basis respectively • ARPP grew by 6.1% and 1.4% on YoY and QoQ basis respectively • IP Volume grew by 7.5% and 7.1% on YoY and QoQ basis respectively • Conducted 4.2 l
Slide 18: Digital & ESG Initiatives
Digital & ESG Initiatives DIGITAL KIMS continued to evolve 100% paperless for clinical workflows. As part of this initiative, KIMS delivered the following features in its EHR application: INITIATIVES • OPD Enhancements • IP Module Enhancements • ER Module • ICU - Fluid Chart • Operation Theatre Modu
Slide 19: Group Operating Performance - 1/2
Group Operating Performance - 1/2 IP VOLUME (‘000) OP VOLUME (‘000) 7.9% 7.1% 9.9% 2.6% 191 50 1,608 421 177 1,462 411 46 46 382 137 1,014 FY22 FY23 FY24 Q1 FY24 Q4 FY24 Q1 FY25 FY22 FY23 FY24 Q1 FY24 Q4 FY24 Q1 FY25 OCCUPANCY ARPOB (‘000) (1.7%) 6.6% 12.2% 58.5% 1.5% 52.9% 31.9 38.4 51.4% 29.9 34.3
Slide 20: Group Operating Performance - 2/2
Group Operating Performance - 2/2 Particulars FY22 FY23 FY24 Q1 FY24 Q4 FY24 Q1 FY25 Bed Capacity 3,064 3,940 3,975 3,975 3,975 3,975 Operational Beds 2,590 3,468 3,503 3,503 3,503 3,503 Census Beds 2,246 2,960 2,989 2,989 2,989 2,989 Non Census Beds 344 508 514 514 514 514 Occupied Beds 1,793 2,071
Slide 21: Group Financial Performance
Group Financial Performance (Rupees in Millions) TOTAL REVENUE EBITDA 12.9% 8.7% 3.7% 13.0% 25,112 6,930 6,535 1,840 6,376 1,602 1,628 22,235 6,299 6,091 5,361 16,711 FY22 FY23 FY24 Q1 FY24 Q4 FY24 Q1 FY25 FY22 FY23 FY24 Q1 FY24 Q4 FY24 Q1 FY25 PBT* PAT* (4.2%) (2.2%) 27.0% 32.7% 4,701 1,272 3,510 9
Slide 22: Operational and Financial Performance - 1/2
Operational and Financial Performance - 1/2 KIMS Telangana (KIMS) Andhra Pradesh (KIMS) Particulars FY22 FY23 FY24 Q1 FY24 Q4 FY24 Q1 FY25 FY22 FY23 FY24 Q1 FY24 Q4 FY24 Q1 FY25 Bed Capacity 1,200 1,200 1,200 1,200 1,200 1,200 1864 1879 1,914 1914 1,914 1,914 Operational Beds 1,035 1,085 1,085 1,085
Slide 23: Operational and Financial Performance - 2/2
Operational and Financial Performance - 2/2 Sunshine, Nagpur & Group Sunshine Nagpur Group Particulars FY23 FY24 Q1 FY24 Q4 FY24 Q1 FY25 FY23** FY24 Q1 FY24 Q4 FY24 Q1 FY25 FY22 FY23 FY24 Q1 FY24 Q4 FY24 Q1 FY25 Bed Capacity 527 527 527 527 527 334 334 334 334 334 3,064 3,940 3,975 3,975 3,975 3,975
Slide 24: Speciality Mix
Speciality Mix Others Cardiac Science 22% 16% Renal Sciences 9% Mother & Child 10% Group Q1FY25 Organ Oncology Transplant 6% 3% Gastric Sciences 9% Neuro Sciences 10% Orthopaedics 15% 23 Private & Confidential
Slide 25: Payor & Cluster Profile
Payor & Cluster Profile PAYOR MIX CLUSTER TOTAL REVENUE Maharashtra 8% Andhra Pradesh Aarogyasri 26% 7% Cash Telangana Corporate Group 66% 13% 53% Q1FY25 Group Q1FY25 CLUSTER EBITDA Maharashtra Insurance 5% 27% Andhra Pradesh 24% Group Telangana 71% Q1FY25 1) Telengana - Secunderad , Kondapur, Begum
Slide 26: Key Achievements in Q1 FY25
Key Achievements in Q1 FY25 25 Private & Confidential
Slide 27: Key Achievements in Q1 FY25
Key Achievements in Q1 FY25 26 Private & Confidential
Slide 28: Key to our success
Key to our success Doctor Affordable Partnerships Quality Care Modern Medical Infra 27 Private & Confidential
Slide 29: KIMS has a disciplined growth strategy in adjacent markets
KIMS has a disciplined growth strategy - strategically grow in adjacent markets some of which are ‘natural extensions’ KIMS Plans to Grow into Markets that are Adjacent to the Current Core Markets of AP and Telangana Central & Western India (Mumbai, Indore, Aurangabad, Nagpur & Raipur): KIMS flagshi
Slide 30: Expansion plans
Expansion plans Current Incremental Approx. Expected Year of Units New Departments Beds Beds Capex Operation Nashik - 300 All Specialities 200-250 Cr Q2 FY25 Vizag QNRI - 250 All Specialities 170-180 Cr Q2 FY25 Bangalore (Project-1) - 415 All Specialities 350-400 Cr Q4 FY25 Bangalore (Project-2) - 2
Slide 31: Queen's NRI Hospital, Vizag
Queen’s NRI Hospital, Vizag Location Key equipment • Philips MRI 1.5T • Philips Cathlab • Philips CT • Varian LINAC iX KPIs • Bed Capacity - 250 - Census - 200 > ICU - 97 Queen's NRI Hospital > Wards - 103 - Non Census - 50 - OT's - 5 • Potential ARPOB: 38K - 42K KIMS-ICON Hospital • Key Specialitie
Slide 32: Profit and Loss Statement
Profit and Loss Statement (Rupees in Millions) Consolidated Particulars Q1 FY 25 Q4 FY 24 Q1 FY 24 QoQ(%) YoY(%) Operating Revenue 6,884 6,338 6,060 8.6% 13.6% Other Income 46 38 31 20.3% 48.1% Total Revenue 6,930 6,376 6,091 8.7% 13.8% EBITDA* 1,720 1,527 1,548 12.6% 11.1% EBITDA (%) on operating r
Slide 33: Corporate Structure (As on 30 June'24)
Corporate Structure (As on 30 June'24) th Krishna Institute of Medical Sciences Limited KIMS Secunderabad KIMS Nellore KIMS Rajahmundry KIMS Ongole (100%) (100%) (100%) (100%) AHPL KHEPL KIMS ICON KIMS Saveera KIMS Sunshine KIMS-Manavata SPANV KIMS Hospitals Srikakulam Kondapur Visakhapatnam Anantap
Slide 34: Thank You
Thank You 33 Private & Confidential
Krishna Institute of Medical Sciences — Q1 FY2025 Earnings Presentation on 6ix